Evolus Inc (NASDAQ:EOLS)
| 8.59 Delayed Data As of Feb 28 |  +0.06 / +0.70%Today’s Change | 8.28 Today|||52-Week Range 29.50 | -29.42% Year-to-Date |
Latest EOLS News | Press Releases
| Evolus, Inc. (EOLS) Q4 2019 Earnings Call Transcript Feb 25 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 8.53 |
| Today’s open | 8.33 |
| Day’s range | 8.28 - 8.73 |
| Volume | 738,194 |
| Average volume (3 months) | 627,774 |
| Market cap | $333.6M |
Data as of 02/28/2020
Growth & Valuation
| Earnings growth (last year) | -611.33% |
| Earnings growth (this year) | -60.36% |
| Earnings growth (next 5 years) | +37.75% |
| Revenue growth (last year) | -- |
| P/E ratio | -- |
| Price/Sales | -- |
| Price/Book | 3.29 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| STMLStemline Therapeutic... | +0.23 | +3.97% |
| TCRRTCR2 Therapeutics In... | -0.29 | -2.38% |
| LXRXLexicon Pharmaceutic... | +0.00 | +0.18% |
| NERVMinerva Neuroscience... | +0.10 | +1.39% |
Data as of 02/28/2020
Financials
| Next reporting date | May 7, 2020 |
| EPS forecast (this quarter) | -$0.62 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$46.9M |
| Net profit margin | -- |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Newport Beach, California |
Forecasts
